We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers.
- Authors
Kamada, T.; Haruma, K.; Miyoshi, E.; Mihara, M.; Kitadai, Y.; Yoshihara, M.; Sumii, K.; Kajiyama, G.; Tahara, K.; Mukai, T.; Kawamura, Y.; Hattori, N.
- Abstract
Background: Our previous study demonstrated that Helicobacter pylori eradication was less effective in smokers than in non-smokers. Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow. Aim: To evaluate the effect of cetraxate combined with new triple therapy for the eradication of H. pylori in smokers. Methods: This study had a single-centre, double-blind, randomized non-placebo design. A total of 106 consecutive H. pylori-positive smoking patients were randomly allocated to one of two regimens: one group received omeprazole (20 mg), amoxycillin (1500 mg), and clarithromycin (600 mg) for 7 days (OAC, n=55). The other group recieved OAC plus cetraxate (600 mg) for 7 days (OAC + CET, n=51). The success of H. pylori eradication was evaluated by histology and the 13C-urea breath test at 4 weeks after completion of treatment. Results: By intention-to-treat analysis, the H. pylori eradication rate was 55% in the OAC group and 92% in the OAC + CET group (P < 0.01). By per protocol analysis, the H. pylori eradication rate was 58% in the OAC group and 94% in the OAC + CET group (P < 0.01). Conclusion: Cetraxate combined with new triple therapy increases the eradication of H. pylori in smokers.
- Subjects
ANTI-infective agents; TREATMENT of helicobacter pylori infections; CIGARETTE smokers; PEPTIC ulcer; DISEASES
- Publication
Alimentary Pharmacology & Therapeutics, 2000, Vol 14, Issue 8, p1089
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1046/j.1365-2036.2000.00807.x